These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
851 related articles for article (PubMed ID: 16301835)
1. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. de Gramont A; Van Cutsem E Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835 [TBL] [Abstract][Full Text] [Related]
3. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Shih T; Lindley C Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999 [TBL] [Abstract][Full Text] [Related]
4. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer. Manegold C Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923 [TBL] [Abstract][Full Text] [Related]
5. Angiogenesis inhibition in the treatment of lung cancer. Vokes E; Herbst R; Sandler A Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257 [TBL] [Abstract][Full Text] [Related]
6. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Cohen MH; Gootenberg J; Keegan P; Pazdur R Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060 [TBL] [Abstract][Full Text] [Related]
7. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer. Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548 [TBL] [Abstract][Full Text] [Related]
8. Bevacizumab in non small cell lung cancer. Sandler A Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4613-6. PubMed ID: 17671151 [TBL] [Abstract][Full Text] [Related]
9. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. Sandler A; Gray R; Perry MC; Brahmer J; Schiller JH; Dowlati A; Lilenbaum R; Johnson DH N Engl J Med; 2006 Dec; 355(24):2542-50. PubMed ID: 17167137 [TBL] [Abstract][Full Text] [Related]
10. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Sandler A; Herbst R Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4421s-4425s. PubMed ID: 16857821 [TBL] [Abstract][Full Text] [Related]
11. Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 patients. Le Moulec S; Hadoux J; Gontier E; Chargari C; Helissey C; Lamand V; Tanz R; Farace F; Vedrine L; Bonardel G; Soria JC; Besse B Bull Cancer; 2013 Dec; 100(12):30-7. PubMed ID: 24316967 [TBL] [Abstract][Full Text] [Related]
12. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. Herbst RS; Johnson DH; Mininberg E; Carbone DP; Henderson T; Kim ES; Blumenschein G; Lee JJ; Liu DD; Truong MT; Hong WK; Tran H; Tsao A; Xie D; Ramies DA; Mass R; Seshagiri S; Eberhard DA; Kelley SK; Sandler A J Clin Oncol; 2005 Apr; 23(11):2544-55. PubMed ID: 15753462 [TBL] [Abstract][Full Text] [Related]
13. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Goulart B; Ramsey S Value Health; 2011; 14(6):836-45. PubMed ID: 21914503 [TBL] [Abstract][Full Text] [Related]
15. Emerging safety data for bevacizumab in advanced non-small-cell lung cancer. Hirsh V Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S62-70. PubMed ID: 21885001 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Crinò L; Dansin E; Garrido P; Griesinger F; Laskin J; Pavlakis N; Stroiakovski D; Thatcher N; Tsai CM; Wu YL; Zhou C Lancet Oncol; 2010 Aug; 11(8):733-40. PubMed ID: 20650686 [TBL] [Abstract][Full Text] [Related]
17. Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data. McDermott DF; George DJ Cancer Treat Rev; 2010 May; 36(3):216-23. PubMed ID: 20116176 [TBL] [Abstract][Full Text] [Related]
18. Bevacizumab in non-small-cell lung cancer: a review. Planchard D Expert Rev Anticancer Ther; 2011 Aug; 11(8):1163-79. PubMed ID: 21916570 [TBL] [Abstract][Full Text] [Related]
19. Role of bevacizumab for the treatment of non-small-cell lung cancer. Ramalingam S; Belani CP Future Oncol; 2007 Apr; 3(2):131-9. PubMed ID: 17381412 [TBL] [Abstract][Full Text] [Related]
20. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. Lara PN; Douillard JY; Nakagawa K; von Pawel J; McKeage MJ; Albert I; Losonczy G; Reck M; Heo DS; Fan X; Fandi A; Scagliotti G J Clin Oncol; 2011 Aug; 29(22):2965-71. PubMed ID: 21709202 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]